MA41809A - Biotine pour le traitement de la sclérose latérale amyotrophique - Google Patents
Biotine pour le traitement de la sclérose latérale amyotrophiqueInfo
- Publication number
- MA41809A MA41809A MA041809A MA41809A MA41809A MA 41809 A MA41809 A MA 41809A MA 041809 A MA041809 A MA 041809A MA 41809 A MA41809 A MA 41809A MA 41809 A MA41809 A MA 41809A
- Authority
- MA
- Morocco
- Prior art keywords
- biotin
- treatment
- lateral sclerosis
- amyotrophic lateral
- nmo
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 2
- 229960002685 biotin Drugs 0.000 title abstract 2
- 235000020958 biotin Nutrition 0.000 title abstract 2
- 239000011616 biotin Substances 0.000 title abstract 2
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Ceramics (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Farming Of Fish And Shellfish (AREA)
Abstract
L'invention concerne l'utilisation de la biotine pour le traitement de la sclérose latérale amyotrophique, ainsi que pour les neuropathies périphériques démyélinisantes et la neuromyélite optique (nmo).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (fr) | 2015-03-26 | 2015-03-26 | Biotin pour le traitement de la sclérose latérale amyotrophique |
| PCT/EP2016/056696 WO2016151132A1 (fr) | 2015-03-26 | 2016-03-25 | Biotine pour le traitement de la sclérose latérale amyotrophique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41809A true MA41809A (fr) | 2018-01-30 |
| MA41809B1 MA41809B1 (fr) | 2019-12-31 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41809A MA41809B1 (fr) | 2015-03-26 | 2016-03-25 | Biotine pour le traitement de la sclérose latérale amyotrophique |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (fr) |
| EP (2) | EP3072513A1 (fr) |
| JP (1) | JP6752874B2 (fr) |
| KR (1) | KR20170131543A (fr) |
| CN (2) | CN107405335A (fr) |
| AU (1) | AU2016238759B2 (fr) |
| BR (1) | BR112017020408A2 (fr) |
| CA (1) | CA2980660A1 (fr) |
| CY (1) | CY1122374T1 (fr) |
| DK (1) | DK3273957T3 (fr) |
| EA (1) | EA034394B1 (fr) |
| ES (1) | ES2748354T3 (fr) |
| HR (1) | HRP20191491T1 (fr) |
| HU (1) | HUE046116T2 (fr) |
| IL (1) | IL254619B (fr) |
| LT (1) | LT3273957T (fr) |
| MA (1) | MA41809B1 (fr) |
| ME (1) | ME03567B (fr) |
| PL (1) | PL3273957T3 (fr) |
| PT (1) | PT3273957T (fr) |
| RS (1) | RS59149B1 (fr) |
| SI (1) | SI3273957T1 (fr) |
| SM (1) | SMT201900548T1 (fr) |
| WO (1) | WO2016151132A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (fr) | 2015-03-26 | 2016-09-28 | Medday | Biotin pour le traitement de la sclérose latérale amyotrophique |
| EP3275439A1 (fr) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Procédé de traitement de l'encéphalopathie hépatique |
| EP3893823A4 (fr) * | 2018-12-11 | 2022-11-02 | Myospots Australia Pty Ltd | Tampon adhésif |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
| US20240082296A1 (en) * | 2020-10-09 | 2024-03-14 | Tx Medic Ab | Treatment of muscle atrophy using dextran sulfate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| CN1802170A (zh) | 2002-09-27 | 2006-07-12 | 比奥根艾迪克Ma公司 | 利用IFN－β治疗慢性炎性脱髓鞘性多神经病 |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| JP6152090B2 (ja) * | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 視神経脊髄炎を処置するための組成物および方法 |
| EA201791043A1 (ru) * | 2011-07-13 | 2017-09-29 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
| WO2014177286A1 (fr) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotine pour son utilisation dans le traitement d'une adrénoleucodystrophie liée à l'x |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (fr) | 2015-03-26 | 2016-09-28 | Medday | Biotin pour le traitement de la sclérose latérale amyotrophique |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/fr not_active Ceased
-
2016
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/fr not_active Ceased
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 CA CA2980660A patent/CA2980660A1/fr not_active Abandoned
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/fr unknown
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/fr active Active
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 SM SM20190548T patent/SMT201900548T1/it unknown
- 2016-03-25 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko not_active Withdrawn
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3021970B1 (fr) | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs | |
| MA40576A (fr) | Anticorps et immunoconjugués anti-her2 | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| MA71420A (fr) | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaîne légère et d'autres tumeurs malignes hématologiques positives à cd38 | |
| EP3642667C0 (fr) | Lentille de contact d'orthokératologie pour le traitement de la myopie | |
| MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA41060B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA55434B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
| MA43018B1 (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA39095A1 (fr) | Anticorps et immunoconjugués anti-cd33 | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA41010A (fr) | Compositions comprenant des souches bactériennes | |
| MA38827A1 (fr) | Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives | |
| MA41809B1 (fr) | Biotine pour le traitement de la sclérose latérale amyotrophique | |
| MA52216B1 (fr) | Mirikizumab pour le traitement de la colite ulcéreuse | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux | |
| EP3442562A4 (fr) | Utilisation d'il-22 pour le traitement de l'entérocolite nécrosante | |
| MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
| MA42419B1 (fr) | Méthode de traitement de l'encéphalopathie hépatique | |
| MA39355B2 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| TN2016000111A1 (fr) | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose. | |
| MA41104A (fr) | Compositions comprenant des souches bactériennes |